Department of Otolaryngology, Hennepin County Medical Center, University of Minnesota, Minneapolis, MN, USA.
J Orthop Trauma. 2011 Jun;25(6):358-65. doi: 10.1097/BOT.0b013e3181f9aba9.
To demonstrate that tissue ultrafiltration catheters are safe to place and use in an injured lower extremity, measure tissue pressures as well as the current standard of care, and effectively remove interstitial fluid for analysis of biomarkers.
Institutional Review Board-approved, prospective pilot study.
Metropolitan Level I trauma center.
All patients who presented to the emergency department with a tibial fracture met the inclusion and exclusion criteria and gave informed consent were enrolled. A total of 10 patients were studied.
All subjects were treated with two types of percutaneous intramuscular catheters in both the anterior and deep posterior compartments of the leg for 24 hours. One catheter was a conventional indwelling intramuscular pressure catheter (Stryker Quick Pressure Monitor, Kalamazoo, MI), whereas the other was an experimental combined pressure monitoring/tissue ultrafiltration catheter (Compartment Monitoring System [CMS] catheter; Twin Star Medical, Inc, Minneapolis, MN).
Safety of device, intramuscular pressure values, and quantity of fluid removed (from CMS catheter only).
No serious device-related complications occurred. There was reasonable correlation between the pressures measured by the CMS and Stryker catheters. Average decrease in intramuscular pressure from baseline to final pressure was 11.3 ± 2.8 mm Hg in the anterior compartment (P = 0.003 by two-tailed paired t test) and 5.9 ± 1.4 mm Hg in the deep posterior compartment (P = 0.01). Ultrafiltrate analysis revealed that lactate dehydrogenase and creatine kinase levels were markedly elevated over serum levels. No patient needed fasciotomy or developed compartment syndrome during the study period.
This pilot study of CMS catheters demonstrates safety of CMS catheter use. Assay of the ultrafiltrate may provide greater sensitivity to muscle injury; further research of this approach is warranted.
证明组织超滤导管在受伤下肢中放置和使用是安全的,能够测量组织压力以及当前的标准护理方法,并有效去除间质液以分析生物标志物。
机构审查委员会批准的前瞻性试点研究。
大都市一级创伤中心。
所有符合纳入和排除标准并知情同意的急诊科就诊的胫骨骨折患者均被纳入研究。共研究了 10 名患者。
所有患者均在腿部前侧和深部后侧的两个部位接受两种类型的经皮肌内导管治疗 24 小时。一种导管是常规留置肌内压导管(Stryker Quick Pressure Monitor,Kalamazoo,MI),另一种是实验性联合压力监测/组织超滤导管(Compartment Monitoring System [CMS] 导管;Twin Star Medical,Inc,Minneapolis,MN)。
设备安全性、肌内压值和去除的液体量(仅来自 CMS 导管)。
未发生与设备相关的严重并发症。CMS 和 Stryker 导管测量的压力之间存在合理的相关性。前侧肌间隙的肌内压从基线到最终压力的平均下降为 11.3 ± 2.8mmHg(双侧配对 t 检验,P = 0.003),深部后侧肌间隙的平均下降为 5.9 ± 1.4mmHg(P = 0.01)。超滤液分析显示,乳酸脱氢酶和肌酸激酶水平明显高于血清水平。在研究期间,没有患者需要筋膜切开术或发生筋膜间室综合征。
本 CMS 导管的试点研究证明了 CMS 导管使用的安全性。超滤液分析可能提供对肌肉损伤的更高敏感性;需要进一步研究这种方法。